Total Current Assets Total Other Assets Total Assets Total Current Liabilities Total Liabilities Total Citius Pharmaceuticals, Inc. Stockholders’ Equity Total Equity Balance Balance Total Liabilities and Equity Gross Profit Total Operating Expenses Operating Loss Total Other Income (Expense), Net Loss before Income Taxes Net Loss Net loss Net loss applicable to common stockholders Balance (in Shares) Balance (in Shares) Equity Components [Axis] Net Cash Used In Operating Activities Cash flows from operations Net Cash Used in Investing Activities Net Cash Provided By Financing Activities Net Change in Cash and Cash Equivalents Cash and Cash Equivalents - Beginning of Period Cash and Cash Equivalents - End of Period Nature of Operations, Basis of Presentation and Summary of Significant Accounting Policies [Abstract] Going Concern Uncertainty and Management’s Plan [Abstract] Revenue Recognition and Accounts Receivable [Abstract] Product and Service [Axis] Inventory [Abstract] Schedule of Inventory [Abstract] Total Inventory Prepaid Expenses [Abstract] Schedule of Prepaid Expenses [Abstract] Total Prepaid expenses In-Process Research and Development, Net [Abstract] Total Consolidated Entities [Axis] Patent and Technology License Agreements [Abstract] Debt Agreements [Abstract] Schedule of Term Loan Agreement [Abstract] Notes payable, net of deferred financing costs Notes payable, net of deferred financing fees Stockholders’ Equity [Abstract] Option Shares, Outstanding balance Option Shares, Outstanding balance Stock plan options outstanding Options outstanding Weighted- Average Exercise Price, Outstanding balance Weighted- Average Exercise Price, Outstanding balance Exercise price (in Dollars per share) Aggregate Intrinsic Value, Outstanding balance Aggregate Intrinsic Value, Outstanding balance Aggregate intrinsic value (in Dollars) Related and Nonrelated Parties [Axis] Derivative Instrument [Axis] Class of Warrant or Right [Axis] Total Common shares reserved Class of Stock [Axis] Commitments and Contingencies [Abstract] Schedule of Lease Expense [Abstract] Total lease cost Schedule of Maturities of Lease Liabilities [Abstract] Total lease payments Schedule of Lease [Abstract] Total lease assets Operating lease right-of-use asset, net Total lease liabilities Present value of lease liabilities Gain on Sale of New Jersey Net Operating Losses [Abstract] Nasdaq Listing [Abstract] Subsequent Events [Abstract] ASSETS Assets Current Assets: Cash and cash equivalents Cash Accounts receivable, net of allowances Deposits In-process research and development, net of accumulated amortization Goodwill Goodwill (in Dollars) LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities: Accounts payable License payable Accrued expenses Accrued compensation Note payable Operating lease liability Current Deferred tax liability Operating lease liability – noncurrent Non-current Commitments and Contingencies Stockholders’ Equity: Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding Preferred stock value issued (in Dollars) Preferred stock, par value (in Dollars per share) Preferred stock par value (in Dollars per share) Preferred stock, shares authorized (in Shares) Preferred stock, shares issued (in Shares) Preferred stock shares of votes Preferred stock, shares outstanding (in Shares) Common stock - $0.001 par value; 250,000,000 shares authorized; 27,452,570 and 18,067,744 shares issued and outstanding at June 30, 2026 and September 30, 2025, respectively Common stock, par value (in Dollars per share) Common stock, shares authorized (in Shares) Common stock authorized Common stock, shares issued (in Shares) Common stock, shares outstanding (in Shares) Additional paid-in capital Accumulated deficit Non-controlling interest Revenues Net Revenue Operating Expenses Research and development Research and development, net balance Amortization of in-process research and development General and administrative Stock-based compensation – general and administrative Stock-based compensation expense Other Income (Expense) Interest income Gain on sale of New Jersey net operating losses Income tax expense (benefit) Net Loss Per Share - Basic (in Dollars per share) Net Loss Per Share - Diluted (in Dollars per share) Weighted Average Common Shares Outstanding Basic (includes pre-funded warrants) (in Shares) Diluted (includes pre-funded warrants) (in Shares) Issuance of common stock, net of costs Issuance of common stock, net of costs (in Shares) Issuance of common stock, net of costs October 2025 sale of common stock and pre-funded warrants, net of costs of $75,868 October 2025 sale of common stock and pre-funded warrants, net of costs of $75,868 (in Shares) Sale of common stock and pre-funded warrants, net of costs December 2025 sale of common stock and pre-funded warrants by Citius Oncology, net of costs of $2,872,989 Sale of common stock by Citius Oncology, net of costs Issuance of common stock upon exercise of pre-funded warrants Issuance of common stock upon exercise of pre-funded warrants (in Shares) Issuance of common stock for services Fair value of common stock (in Dollars) Issuance of common stock for services (in Shares) Common stock shares issued Issuance of common stock warrant for note payable extension Stock-based compensation expense Net loss attributable to non-controlling interest Proceeds from exercise of Citius Oncology pre-funded warrants Net proceeds (in Dollars) December 2025 offering costs Issuance of common stock and pre-funded warrants in April 2026 registered direct offering, net of costs of $546,782 Issuance of common stock and pre-funded warrants in April 2026 registered direct offering, net of costs of $546,782 (in Shares) Direct offering, net of costs Proceeds from exercise of pre-funded warrants Proceeds from exercise of pre-funded warrants (in Shares) Option Shares, Exercised Citius Oncology net proceeds from exercise of warrants, net of costs of $1,770,000 Net of costs Citius Oncology warrants issued for loan agreement Sale of common stock, net of costs of $425,949 Sale of common stock, net of costs of $425,949 (in Shares) Purchase of warrant (in Shares) Sale of common stock, net of costs Issuance of common stock and pre-funded warrants in April 2025 registered direct offering, net of costs of $256,116 Issuance of common stock and pre-funded warrants in April 2025 registered direct offering, net of costs of $256,116 (in Shares) April 2025 registered direct offering, net of costs Issuance of common stock and pre-funded warrants in June 2025 registered direct offering, net of costs of $571,126 Issuance of common stock and pre-funded warrants in June 2025 registered direct offering, net of costs of $571,126 (in Shares) June 2025 registered direct offering, net of costs Sale of Series A preferred stock Cash Flows From Operating Activities: Adjustments to reconcile net loss to net cash used in operating activities: Issuance of common stock for services Issuance of common stock warrant Amortization of operating lease right-of-use asset Amortization of deferred financing costs Amortization of deferred financing costs Deferred income tax expense (benefit) Changes in operating assets and liabilities: Accounts payable Accrued expenses Accrued compensation Operating lease liability Cash Flows From Investing Activities: Cash Flows From Financing Activities: Proceeds from (repayment of) note payable and advance from employee Net proceeds from loan agreement Proceeds from exercise of warrants Exercise of warrants Proceeds from sale of Series A preferred stock Net proceeds from common stock offerings Supplemental Disclosures of Cash Flow Information and Non-cash Transactions: Interest paid Operating lease right-of-use asset and liability recorded Warrants issued for loan agreement included in deferred financing costs Deferred financing costs included in accrued expenses Cost of revenues Interest expense Net loss attributable to non-controlling interest Redemption of Series A preferred stock Accounts receivable, net of allowances Inventory Prepaid expenses License fee payments Repayment of advance from employee Deferred Financing Costs Deferred financing costs Redemption of Series A preferred stock Preferred Stock Common Stock Common Stock [Member]